About Optogard Nanotech
Optogard Nanotech is a company based in Moscow (Russia) founded in 2011. It operates as a B2B. Optogard Nanotech has raised $1.86 million across 1 funding round from investors including Garant. Optogard Nanotech operates in a competitive market with competitors including Liquidia, Sirnaomics, Acorda, NanoSyrinx and Genedit, among others.
- Headquarter Moscow, Russia
-
Sectors
Technology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.86 M (USD)
in 1 rounds
-
Latest Funding Round
$1.86 M (USD), Seed
Aug 23, 2017
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Optogard Nanotech
Optogard Nanotech has successfully raised a total of $1.86M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.86 million completed in August 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Optogard Nanotech
Optogard Nanotech has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Garant.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Legal information and consulting services are provided by Garant.
|
Locked | Locked | Locked |
Investor details for Optogard Nanotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Optogard Nanotech
Investment portfolio details for Optogard Nanotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Optogard Nanotech
Detailed financials for Optogard Nanotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Optogard Nanotech Comparisons
Peer comparison for Optogard Nanotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Optogard Nanotech
Optogard Nanotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Liquidia, Sirnaomics, Acorda, NanoSyrinx and Genedit, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Engineered particles & films for life and material sciences applications
|
|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| Locked | Locked | Locked |
Engaged in the development and commercialization of therapies that improve neurological function.
|
|
| Locked | Locked | Locked |
Drug delivery systems to cell interiors are developed via nanosyringes.
|
|
| Locked | Locked | Locked |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
|
| Locked | Locked | Locked |
RNAi technologies are developed for treating rare orphan diseases.
|
Detailed competitors of Optogard Nanotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Optogard Nanotech
Complete news archive for Optogard Nanotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Optogard Nanotech
Optogard Nanotech was founded in 2011 and raised its 1st funding round 6 years after it was founded.
Optogard Nanotech is headquartered in Moscow, Russia.
Optogard Nanotech is a funded company, having raised a total of $1.86M across 1 funding round to date.
Optogard Nanotech, established in 2011 and currently in Dissolved stage, focuses on leveraging cutting-edge technology, nanotechnology, materials science, and metal structures. Develops innovative nanotech-based technologies for metal and metalloid structures. Adapting to market demands with innovation and client-focused strategies. It continues to evolve, meeting industry challenges with strategic approaches.
Optogard Nanotech's top competitors include Sirnaomics, Arcturus Therapeutics and Acorda.
Optogard Nanotech has 1 investor. Key investors include Garant.